PURPOSE: To evaluate the safety and immunogenicity of a therapeutic human papillomavirus (HPV)16 DNA vaccine administered to women with HPV16+cervical intraepithelial neoplasia (CIN)2/3. EXPERIMENTAL DESIGN: This phase I trial incorporated the standard '3+3'' dose-escalation design with an additional 6 patients allocated to the maximally tolerated dose. Healthy adult women with colposcopically directed, biopsy-proven HPV16+ CIN2/3 received 3 i.m. vaccinations (0.5, 1, or 3 mg) of a plasmid expressing a Sig-E7(detox)-heat shock protein 70 fusion protein on days 0, 28, and 56, and underwent standard therapeutic resection of the cervical squamocolumnar junction at day 105 (week 15). The safety and immunogenicity of the vaccine and histologic outcome based on resection at week 15 were assessed. RESULTS: Fifteen patients were evaluable (3 each at 0.5 and 1mg, 9 at 3 mg). The vaccine was well tolerated: most adverse events were mild, transient injection-site discomfort; no dose-limiting toxicities were observed. Although HPVE7-specific T-cell responses to E7 detected by enzyme-linked immunospot assays (IFN-gamma) were of low frequency and magnitude, detectable increases in response subsequent to vaccination were identified in subjects in the second and third cohorts. Complete histologic regression occurred in 3 of 9 (33%; 7-70% confidence interval) individuals in the highest-dose cohort. Although the difference is not significant, it is slightly higher than would be expected in an unvaccinated cohort (25%). CONCLUSIONS: This HPV16 DNA vaccine was safe and well tolerated. Whereas it seems possible to elicit HPV-specific T-cell responses in patients with established dysplastic lesions, other factors are likely to play a role in lesion regression.
PURPOSE: To evaluate the safety and immunogenicity of a therapeutic human papillomavirus (HPV)16 DNA vaccine administered to women with HPV16+cervical intraepithelial neoplasia (CIN)2/3. EXPERIMENTAL DESIGN: This phase I trial incorporated the standard '3+3'' dose-escalation design with an additional 6 patients allocated to the maximally tolerated dose. Healthy adult women with colposcopically directed, biopsy-proven HPV16+ CIN2/3 received 3 i.m. vaccinations (0.5, 1, or 3 mg) of a plasmid expressing a Sig-E7(detox)-heat shock protein 70 fusion protein on days 0, 28, and 56, and underwent standard therapeutic resection of the cervical squamocolumnar junction at day 105 (week 15). The safety and immunogenicity of the vaccine and histologic outcome based on resection at week 15 were assessed. RESULTS: Fifteen patients were evaluable (3 each at 0.5 and 1mg, 9 at 3 mg). The vaccine was well tolerated: most adverse events were mild, transient injection-site discomfort; no dose-limiting toxicities were observed. Although HPVE7-specific T-cell responses to E7 detected by enzyme-linked immunospot assays (IFN-gamma) were of low frequency and magnitude, detectable increases in response subsequent to vaccination were identified in subjects in the second and third cohorts. Complete histologic regression occurred in 3 of 9 (33%; 7-70% confidence interval) individuals in the highest-dose cohort. Although the difference is not significant, it is slightly higher than would be expected in an unvaccinated cohort (25%). CONCLUSIONS: This HPV16 DNA vaccine was safe and well tolerated. Whereas it seems possible to elicit HPV-specific T-cell responses in patients with established dysplastic lesions, other factors are likely to play a role in lesion regression.
Authors: Mary K Wloch; Larry R Smith; Souphaphone Boutsaboualoy; Luane Reyes; Christina Han; Jackie Kehler; Heather D Smith; Linda Selk; Ryotaro Nakamura; Janice M Brown; Thomas Marbury; Anna Wald; Alain Rolland; David Kaslow; Thomas Evans; Michael Boeckh Journal: J Infect Dis Date: 2008-06-15 Impact factor: 5.226
Authors: Annemieke de Jong; Mariëtte I E van Poelgeest; Jeanette M van der Hulst; Jan Wouter Drijfhout; Gert Jan Fleuren; Cornelis J M Melief; Gemma Kenter; Rienk Offringa; Sjoerd H van der Burg Journal: Cancer Res Date: 2004-08-01 Impact factor: 12.701
Authors: Samuel J McConkey; William H H Reece; Vasee S Moorthy; Daniel Webster; Susanna Dunachie; Geoff Butcher; Jenni M Vuola; Tom J Blanchard; Philip Gothard; Kate Watkins; Carolyn M Hannan; Simone Everaere; Karen Brown; Kent E Kester; James Cummings; Jackie Williams; D Gray Heppner; Ansar Pathan; Katie Flanagan; Nirmalan Arulanantham; Mark T M Roberts; Michael Roy; Geoffrey L Smith; Joerg Schneider; Tim Peto; Robert E Sinden; Sarah C Gilbert; Adrian V S Hill Journal: Nat Med Date: 2003-05-25 Impact factor: 53.440
Authors: Marij J P Welters; Annemieke de Jong; Susan J F van den Eeden; Jeanette M van der Hulst; Kitty M C Kwappenberg; Sabrin Hassane; Kees L M C Franken; Jan Wouter Drijfhout; Gert Jan Fleuren; Gemma Kenter; Cornelis J M Melief; Rienk Offringa; Sjoerd H van der Burg Journal: Cancer Res Date: 2003-02-01 Impact factor: 12.701
Authors: Patti E Gravitt; Cheri Peyton; Cosette Wheeler; Raymond Apple; Russell Higuchi; Keerti V Shah Journal: J Virol Methods Date: 2003-09 Impact factor: 2.014
Authors: Bernadette Ferraro; Matthew P Morrow; Natalie A Hutnick; Thomas H Shin; Colleen E Lucke; David B Weiner Journal: Clin Infect Dis Date: 2011-08-01 Impact factor: 9.079
Authors: Adam Drake; Nikhil S Joshi; Gregory L Szeto; Eric Zhu; Herman N Eisen; Darrell J Irvine Journal: Cancer Immunol Res Date: 2013-10 Impact factor: 11.151
Authors: Ronald D Alvarez; Warner K Huh; Sejong Bae; Lawrence S Lamb; Michael G Conner; Jean Boyer; Chenguang Wang; Chien-Fu Hung; Elizabeth Sauter; Mihaela Paradis; Emily A Adams; Shirley Hester; Bradford E Jackson; T C Wu; Cornelia L Trimble Journal: Gynecol Oncol Date: 2015-11-23 Impact factor: 5.482